Pinpoint Genomics, a developer of molecular assays and genomic-based clinical laboratory services, has unveiled its Pinpoint Dx Lung assay.
The Lung assay is designed to identify and differentiate patients at high, intermediate or low risk of early death after surgery in order to remove a non-squamous, non-small cell lung cancer.
The Pinpoint Dx Lung assay runs on surgical specimens which undergoes routine handling by pathology laboratories, making it immediately available to all patients, and is offered through the company’s clinical laboratory improvement amendment (CLIA) certified laboratory.
The development of the assay is based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to assess the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer.
The company is also developing additional assays for patients with lung and other cancers.